BAJAJ BROKING

Notification
No new Notification messages
Standard Glass Lining IPO is Open!
Apply for the Standard Glass Lining IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Mankind Pharma pledges 56.31% equity in Bharat Serums for NCDs

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Mankind Pharma pledged 56.31% of its shares in Bharat Serums for ₹5,000 crore NCDs. Mankind Pharma share price rose 1%, settling at ₹2,918.55, with a 46% one-year return.

Mankind Pharma news today

Mankind Pharma has pledged an additional 56.31% equity shares of Bharat Serums and Vaccines Ltd (BSV), its wholly owned subsidiary, in favour of Catalyst Trusteeship Ltd. This move secures its listed, rated, and redeemable non-convertible debentures (NCDs) worth ₹5,000 crore, issued in three series. The pledge strengthens the security framework for NCD holders and demonstrates Mankind Pharma’s commitment to meeting its financial obligations.

Also read: M&M unveils BE 6 and XEV 9e Pack Three at ₹26.9 lakh and ₹30.5 lakh

MANKIND PHARMA LIMITED

Trade

2874-45.69 (-1.56 %)

Updated - 08 January 2025
2940.05day high
DAY HIGH
2865.10day low
DAY LOW
302663
VOLUME (BSE)

Key takeaways

  • Equity pledged: 56.31% of BSV shares

  • Subsidiary: Bharat Serums and Vaccines Ltd (BSV)

  • NCD value: ₹5,000 crore

  • Debenture trust deeds date: 10 October 2024

  • Trustee: Catalyst Trusteeship Ltd

Also read: Tata Steel reports 6.17% rise in India’s steel production in Q3FY25

Catalyst Trusteeship secures NCDs

Catalyst Trusteeship Ltd acts as the Common Security Trustee for the NCD holders, ensuring that the pledged equity serves as collateral for the debentures. This arrangement is part of the agreements executed in October 2024, highlighting Mankind Pharma’s strategic approach to managing its financial instruments.

Mankind Pharma’s financial performance

Mankind Pharma continues to deliver strong market performance. The Mankind Pharma share price rose by over 1% to ₹2,918.55 on the BSE. The company’s stock has provided a one-year return of nearly 46%, reflecting investor confidence in its growth trajectory.

NCD Details

Parameter

Details

NCD Value

₹5,000 crore

Number of Series

3

Trustee

Catalyst Trusteeship Ltd

Equity Pledged

56.31% of BSV shares

Debenture Deed Date

10 October 2024

Mankind Pharma share price trends

The Mankind Pharma share price has shown resilience, reflecting positive sentiment in the market. With a 46% one-year return, the stock has outperformed expectations, underscoring the company’s robust financial position and strategic moves.

Mankind Pharma’s pledge of additional equity in Bharat Serums strengthens its financial security and showcases its commitment to fulfilling NCD-related obligations.

Also read: NTPC enters nuclear energy business with NPUNL incorporation

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text